Trials / Completed
CompletedNCT03149081
A "Window Trial" on Boswellia for Breast Cancer Primary Tumors
A "Window Trial" on Boswellia, an Extract From Frankincense, for Breast Primary Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Medical University of South Carolina · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether oral administration of Boswellia causes biological changes in primary tumors of breast cancer patients.
Detailed description
To determine whether oral administration of Boswellia serrata causes biological changes related to angiogenesis (CD31), apoptosis (DNA fragmentation), and cell proliferation (Ki67) in primary tumors of breast cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Boswellia | Boswellia is an extract from frankincense |
Timeline
- Start date
- 2017-08-31
- Primary completion
- 2024-04-29
- Completion
- 2024-04-29
- First posted
- 2017-05-11
- Last updated
- 2024-04-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03149081. Inclusion in this directory is not an endorsement.